Do weight loss injections affect your immune system?

Does tirzepatide or semaglutide weaken your immune defences?

It is worth naming the concern directly, because it is a common one: people sometimes assume that any powerful medicine must be lowering their body's defences somewhere. That is understandable, but it does not reflect how GLP-1 medicines work.

Tirzepatide (Mounjaro) activates GIP and GLP-1 receptors, which are mainly involved in regulating appetite signals in the brain, slowing how quickly food leaves the stomach, and influencing blood-sugar levels. Semaglutide (Wegovy) works along the GLP-1 pathway alone. Neither medicine interferes with your bone marrow, your lymph nodes, or the production of the white blood cells and antibodies that form your immune defences. The clinical trial programmes (including SURMOUNT-1 for tirzepatide and STEP 1 for semaglutide, each involving thousands of adults over more than a year) did not identify immune suppression as a side effect. The most commonly reported effects were gastrointestinal: nausea, changes in bowel habit, and reflux, particularly after starting or increasing a dose.

If you are curious about the broader picture of what these medicines do inside the body, our page on what weight loss injections do to your body covers the mechanisms in fuller detail.

Is there any evidence GLP-1 medicines affect inflammation?

Here the picture gets more interesting, and the honest answer is: possibly, in a beneficial direction, but the science is still developing.

GLP-1 receptors are present not just in the gut and brain but also in certain immune cells and tissues. Some pre-clinical and early human research has found that GLP-1 receptor activation may dampen certain inflammatory signals — particularly the low-grade, chronic inflammation that is closely associated with obesity itself. This is genuinely interesting territory for researchers. However, it would be premature to describe current licensed weight-management doses of these medicines as anti-inflammatory treatments; that is not what they are licensed for, and clinical evidence at this level of detail remains limited and ongoing.

What is better established is the indirect effect. Obesity itself is associated with a state of chronic low-grade inflammation, elevated markers such as C-reactive protein are common. Studies have consistently shown that significant weight reduction, however achieved, tends to reduce these inflammatory markers over time. So if tirzepatide or semaglutide leads to meaningful weight loss, some improvement in inflammatory status may follow. Whether that constitutes a benefit to your immune system in any practical sense depends on your individual health picture, and it is the kind of question worth raising with your own GP or prescriber.

You might also be interested in how these medicines interact with other body systems, there is a separate discussion worth reading about how weight loss injections may affect the liver, where the metabolic effects of weight loss are particularly well studied.

Are there any situations where immune health needs extra thought on these medicines?

For most people, immune health is not a primary consideration when starting a weight-management medicine. A few specific situations are worth awareness, though.

People who are already immunocompromised (for example, those taking immunosuppressant drugs after organ transplants, or those with certain autoimmune conditions) will need a careful prescriber review before starting any new medicine. That is true of most medicines, not just GLP-1 treatments. In those cases, your existing specialist should be part of the conversation.

Separately, because GLP-1 medicines can occasionally cause gastrointestinal side effects, people who experience prolonged vomiting or diarrhoea need to stay well hydrated; significant dehydration can put strain on kidney function, which in turn affects how well the body handles infection. This is one reason prescribers monitor for those symptoms carefully, particularly early in treatment.

There is also a question some people raise about fertility and whether treatment could affect reproductive or hormonal immunity, if that is on your mind, our page on whether weight loss injections affect fertility addresses it specifically. And if you have questions about which medicines are actually licensed in the UK for weight management, NICE's guidance on weight loss injections sets out the official position clearly.

You can also explore the full range of weight loss injections available in the UK and what distinguishes them from one another, including newer and more experimental approaches such as stem cell injection for weight loss, which some people ask about when comparing their options.

What should you do if you notice something unexpected while on treatment?

Recurrent infections, slow wound healing, or anything that feels like your body is struggling to fight things off, these are worth mentioning to your prescriber rather than waiting until your next scheduled review. The same applies to any symptom that concerns you, whether or not you can connect it to the medicine.

The MHRA's Yellow Card scheme exists precisely for this: reporting a suspected side effect does not mean the medicine caused it, but it contributes to the ongoing safety surveillance that keeps medicines licences current. You can submit a report at yellowcard.mhra.gov.uk. Prescribers at services like nume's consultation service conduct a clinical review before every repeat order, so there is always a point at which you can raise a concern with a real clinician, not a chatbot. If you are thinking about treatment and have questions about your own health history, starting with a free consultation means those questions get answered properly before anything is prescribed. Our clinical team is there for exactly that.